employee
employee
employee
employee
GRNTI 68.41 Ветеринария
Background. Canine epitheliotropic cutaneous T-cell lymphoma (eCTCL) is thought to represent a disease homologue to human mycosis fungoides (MF). In human MF, neoplastic cells are phenotypically consistent with resident effector memory T cells, a population that remains for an extended period within tissue without circulating. Dogs with eCTCL often present with lesions in multiple locations, raising the question of whether the neoplasm is of the same T-cell subpopulation or not. Objectives: To characterize the antigen receptor gene rearrangements of lymphocytes from skin and blood of dogs with eCTCL to determine if neoplastic clones are identical. Animals. Fourteen dogs with eCTCL. Materials and methods. Histological and immunohistochemical examination, and PCR for antigen receptor rearrangement (PARR) for T-cell receptor gamma (TRG) performed on multiple cutaneous biopsy samples and blood. Results. All skin biopsies contained cluster of differentiation (CD)3-positive neoplastic lymphocytes. Within individual dogs, all skin biopsies revealed identical TRG clonality profiles, suggesting that the same neoplastic clone was present in all sites. In the blood, a matching clone was found in six of 14 dogs, a unique clone was observed in nine of 14 dogs, and no clone was detected in two of 14 dogs. Conclusions. These findings show that canine eCTCL lesions in multiple locations harbour the same neoplastic clone, neoplastic lymphocytes do not remain fixed to the skin and instead can circulate via blood, differing clones can be identified in skin versus blood, and circulating neoplastic cells can be detected without lymphocytosis.
epitheliotropic cutaneous T-cell lymphoma, dogs, tumor clonality, antigen receptor gene rearrangements of lymphocytes
1. Kempf W., Zimmermann A.K., Mitteldorf C., Cutaneous lymphomas - An update 2019., Hematol Oncol., 2019, No. 37(S1), pp. 43-47.
2. Campbell J.J., Clark R.A., Watanabe R., Kupper T.S., Sézary syndrome and mycosis fungoides arise from distinct T-cell subsets: A biologic rationale for their distinct clinical behaviors, Blood, 2010, No. 116(5), pp. 767-771.
3. Willemze R., Meijer C.J., Classification of Cutaneous T-Cell Lymphoma: From Alibert to WHO-EORTC. J Cutan Pathol., 2006, No. 33(S1), pp. 18-26.
4. Willemze R., Cerroni L., Kempf W., Berti E., Facchetti F., Swerdlow S.H. et al., The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas, Blood 2019, No. 133(16), pp. 1703-1714.
5. Moore P.F., Affolter V.K., Graham P.S., Hirt B., Canine epitheliotropic cutaneous T-cell lymphoma: An investigation of T-cell receptor immunophenotype, lesion topography and molecular clonality, Vet Dermatol., 2009, No. 20(5-6), pp. 569-76.
6. Chan C.M., Frimberger A.E., Moore A.S., Clinical outcome and prognosis of dogs with histopathological features consistent with epitheliotropic lymphoma: a retrospective study of 148 cases (2003-2015), Vet Dermatol., 2018, No. 29(2), pp. 154-e59.
7. Ewing T.S., Pieper J.B., Stern A.W., Prevalence of CD20 + cutaneous epitheliotropic T-cell lymphoma in dogs: a retrospective analysis of 24 cases (2011-2018) in the USA, Vet Dermatol., 2019, No. 30(1), pp. 51-e14.
8. Moore P.F., Olivry T., Naydan D., Animal model canine cutaneous epitheliotropic lymphoma (mycosis fungoides) is a proliferative disorder of CD8+ T Cells, Am J Pathol., 1994, No. 144(2), pp. 421-429.
9. Watanabe R., Gehad A., Yang C., Scott L.S., Teague J.E., Schlapbach C. et al., Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells, Sci. Transl Med., 2015, No. 7(279), pp. 279ra39.
10. Clark R.A., Resident memory T cells in human health and disease, Sci Transl Med., 2015, No. 7(269), pp. 269rv1.
11. Jubala C.M., Wojcieszyn J.W., Valli V.E.O., Getzy D.M., Fosmire S.P., Coffey D. et al. CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma, Vet Pathol., 2005, No. 42(4), pp. 468-76.
12. Valli V.E., Vernau W., de Lorimier L.P., Graham P.S., Moore P.F., Canine indolent nodular lymphoma, Vet Pathol., 2006, No. 43, pp. 241-56.
13. Keller S.M., Moore P.F., A novel clonality assay for the assessment of canine T cell proliferations, Vet Immunol Immunopathol., 2012, No. 145(1-2), pp. 410-9.
14. Keller S.M., Moore P.F., Rearrangement patterns of the canine TCRγ locus in a distinct group of T cell lymphomas, Vet Immunol Immunopathol., 2012, No. 145(1-2), pp. 350-61.
15. Rütgen BC, Flickinger I, Wolfesberger B, Litschauer B, Fuchs-Baumgartinger A, Hammer SE et al. Cutaneous T-cell lymphoma - Sézary syndrome in a Boxer. Vet Clin Pathol 2016;45(1):172-8.
16. Fontaine J., Heimann M., Day M.J., Canine cutaneous epitheliotropic T-cell lymphoma: a review of 30 cases, Vet Dermatol, 2010, No. 21(3), pp. 267-75.
17. Clark R.A., Human skin in the game, Sci Transl Med., 2013, No. 5(204), pp. 204ps13.
18. Klicznik M.M., Morawski P.A., Höllbacher B., Varkhande S.R., Motley S.J., Kuri-Cervantes L., Goodwin E. et al., Human CD4 + CD103 + cutaneous resident memory T cells are found in the circulation of healthy individuals, Sci Immunol., 2019, No. 4(37), eaav8995.
19. Keller R.L., Avery A.C., Burnett R.C., Walton J.A., Olver C.S., Detection of neoplastic lymphocytes in peripheral blood of dogs with lymphoma by polymerase chain reaction for antigen receptor gene rearrangement, Vet Clin Pathol., 2004, No. 33(3), pp. 145-9.
20. Yamazaki J., Baba K., Goto-Koshino Y., Setoguchi-Mukai A., Fujino Y., Ohno K. et al,. Quantitative assessment of minimal residual disease (MRD) in canine lymphoma by using realtime polymerase chain reaction, Vet Immunol Immunopathol., 2008, No. 126(3-4), pp. 321-31.
21. Hiyoshi-Kanemoto S., Goto-Koshino Y., Fukushima K., Takahashi M., Kanemoto H., Uchida K. et al., Detection of circulating tumor cells using GeneScan analysis for antigen receptor gene rearrangements in canine lymphoma patients, J Vet Med Sci., 2016, No. 78(5), pp. 877-81.
22. Lana S.E., Jackson T.L., Burnett R.C., Morley P.S., Avery A.C., Utility of polymerase chain reaction for analysis of antigen recept rearrangement in staging and predicting prognosis in dogs with lymphoma, J Vet Intern Med, 2006, No. 20(2), pp. 329-34.
23. Sato M., Yamazaki J., Goto-Koshino Y., Takahashi M., Fujino Y., Ohno K. et al., Increase in minimal residual disease in peripheral blood before clinical relapse in dogs with lymphoma that achieved complete remission after chemotherapy, J Vet Intern Med, 2011, No. 25(2), pp. 292-6.
24. Scarisbrick J.J., Whittaker S., Evans A.V., Fraser-Andrews E.A., Child F.J., Dean A. et al., Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma, Blood, 2001, No. 97(3), pp. 624-30.
25. Fraser-Andrews E.A., Woolford A.J., Russell-Jones R., Seed P.T., Whittaker S.J., Detection of a peripheral blood T cell clone is an independent prognostic marker in mycosis fungoides, J Invest Dermatol., 2000, No. 114(1), pp. 117-21.
26. Sato M., Yamzaki J., Goto-Koshino Y., Takahashi M., Fujino Y., Ohno K. et al., The prognostic significance of minimal residual disease in the early phases of chemotherapy in dogs with highgrade B-cell lymphoma, Vet J., 2013, No. 195(3), pp. 319-24.
27. Yamazaki J., Takahashi M., Setoguchi A., Fujino Y., Ohno K., Tsujimoto H., Monitoring of minimal residual disease (MRD) after multidrug chemotherapy and its correlation to outcome in dogs with lymphoma: a proof-of-concept pilot study, J Vet Intern Med., 2010, No. 24(4), pp. 897-903.
28. Cescon D.W., Bratman S.V., Chan S.M., Siu L.L., Circulating tumor DNA and liquid biopsy in oncology, Nat Cancer, 2020, No. 1(3), pp. 276-90.
29. Thilakaratne D.N., Mayer M.N., Macdonald V.S., Jackson M.L., Trask B.R., Kidney B.A., Article clonality and phenotyping of canine lymphomas before chemotherapy and during remission using polymerase chain reaction (PCR) on lymph node cytologic smears and peripheral blood, Can Vet J., 2010, No. 51(1), pp. 79-84.
30. Keller S.M., Vernau W., Moore P.F., Clonality testing in veterinary medicine: a review with diagnostic guidelines, Vet Pathol., 2016, No. 53(4), pp. 711-25.
31. Brady S.P., Magro C.M., Diaz-Cano S.J., Wolfe H.J., Analysis of clonality of atypical cutaneous lymphoid infiltrates associated with drug therapy by PCR/DGGE, Hum Pathol., 1999, No. 30(2), pp. 130-36.
32. Magro C.M., Crowson A.N., Kovatich A.J., Burns F., Druginduced reversible lymphoid dyscrasia: a clonal lymphomatoid dermatitis of memory and activated T cells, Hum Pathol., 2003, No. 34(2), pp. 119-29.
33. Magro C.M., Daniels B.H., Crowson A.N., Drug induced pseudolymphoma. Semin Diagn Pathol., 2018, No. 35(4), pp. 247-59.
34. Lee P.L., Yee C., Savage P.A., Fong L., Brockstedt D., Weber J.S. et al., Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients, Nat Med., 1999, No. 5(6), pp. 677-85.
35. Qurollo B.A., Davenport A.C., Sherbert B.M., Grindem C.B., Birkenheuer A.J., Breitschwerdt E.B., Infection with Panola Mountain Ehrlichia sp. in a dog with atypical lymphocytes and clonal T-cell expansion, J Vet Inter Med., 2013, No. 27(5), pp. 1251-5.
36. Melendez-Lazo A., Jasensky A.K., Jolly-Frahija I.T., Kehl A., Műller E., Mesa-Sánchez I., Clonality testing in the lymph nodes from dogs with lymphadenomegaly due to Leishmania infantum infection, PLoS One, 2019, No. 14(12), pp. e0226336.
37. Boon T., Coulie P.G., Van den Eynde B.J., van der Bruggen P., Human T cell responses against melanoma, Ann Rev Immunol., 2006, No. 24, pp. 175-208.
